Analyst 'would not be surprised' to see Takeda retry Iclusig in first-line CML

25 March 2018
takeda_flickr_big-1

Positive long-term results on Iclusig (ponatinib) in chronic myeloid leukemia (CML) have prompted a prominent biotech analyst to suggest that Japanese pharma major Takeda (TYO: 4502) might yet seek approval in the first-line setting.

This drug was one of two oncology assets picked up by Takeda in January 2017 in its $5.2 billion acquisition of Ariad Pharmaceuticals, despite Iclusig’s somewhat checkered history.

It was approved in the USA in December 2012 for resistant or intolerant chronic myeloid leukemia (CML) and philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical